A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

NCT06775275 PHASE2 RECRUITING

This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.

Details

Lead sponsor	The First Affiliated Hospital of Guangzhou Medical University
Phase	PHASE2
Status	RECRUITING
Enrolment	60
Start date	Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Dec 31 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Resectable Lung Non-Small Cell Carcinoma

Interventions

• Adebellizumab
• Bevacizumab
• Platinum-based chemotherapy

Countries

China